Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening.

[1]  P. Mannucci,et al.  Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. , 1997, Circulation.

[2]  P. Ridker,et al.  Age-Specific Incidence Rates of Venous Thromboembolism among Heterozygous Carriers of Factor V Leiden Mutation , 1997, Annals of Internal Medicine.

[3]  M. Prins,et al.  The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). , 1997, The New England journal of medicine.

[4]  F R Rosendaal,et al.  Factor V Leiden: should we screen oral contraceptive users and pregnant women? , 1996, BMJ.

[5]  P. Simmonds,et al.  Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen , 1996, The Lancet.

[6]  B. Dahlbäck.  Are we ready for factor V Leiden screening? , 1996, The Lancet.

[7]  J. Pasi,et al.  Lack of Activated Protein C Resistance in Healthy Hong Kong Chinese Blood Donors - Correlation with Absence of Arg506-Gln Mutation of Factor V Gene , 1996, Thrombosis and Haemostasis.

[8]  J. Vandenbroucke,et al.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen , 1995, The Lancet.

[9]  P. Ridker,et al.  Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.

[10]  J. Clegg,et al.  World distribution of factor V Leiden , 1995, The Lancet.

[11]  F. Ishida,et al.  APC-Resistance and Mnl I Genotype (Gin 506) of Coagulation Factor V Are Rare in Japanese Population , 1995, Thrombosis and Haemostasis.

[12]  P. Reitsma,et al.  Factor V Leiden: An Additional Risk Factor for Thrombosis in Protein S Deficient Families? , 1995, Thrombosis and Haemostasis.

[13]  B. Dahlbäck,et al.  Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. , 1995, American journal of obstetrics and gynecology.

[14]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[15]  P. Reitsma,et al.  Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation , 1994, The Lancet.

[16]  P. Reitsma,et al.  Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. , 1994, Blood.

[17]  B. Dahlbäck,et al.  Multicenter Evaluation of a Kit for Activated Protein C Resistance on Various Coagulation Instruments Using Plasmas from Healthy Individuals , 1994, Thrombosis and Haemostasis.

[18]  B. Dahlbäck,et al.  Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis , 1994, The Lancet.

[19]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[20]  J. Birkmeyer,et al.  The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. , 1994, Archives of internal medicine.

[21]  B. Dahlbäck,et al.  Resistance to activated protein C as a basis for venous thrombosis. , 1994, The New England journal of medicine.

[22]  R. Bertina,et al.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.

[23]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Walker,et al.  A population based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT Study. Anderson FA, Wheeler HB, Goldberg RJ, et al. Arch Intern Med 1991;151:933-8 , 1992 .

[25]  E. Tuddenham,et al.  Epidemiology of coagulation disorders. , 1992, Bailliere's clinical haematology.

[26]  D. Hosmer,et al.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. , 1991, Archives of internal medicine.

[27]  S. Harlap,et al.  Comparing the health risks and benefits of contraceptive choices. , 1991, Family planning perspectives.

[28]  A. Ghosh,et al.  Maternal mortality in Hong Kong 1961–1985 , 1989, British journal of obstetrics and gynaecology.

[29]  C. Lund,et al.  Recommended health-based occupational exposure limits for respiratory irritants , 1985, Springer Netherlands.

[30]  T. Chan,et al.  Deep Vein Thrombosis and Changes in Coagulation and Fibrinolysis after Gynaecological Operations in Chinese: the Effect of Oral Contraceptives and Malignant Disease , 1980, British journal of haematology.

[31]  F. R. Rosendaal.  Factor V Leiden , 1997 .